CLDN20
gene geneOn this page
Summary
CLDN20 (claudin 20, HGNC:2042) is a protein-coding gene on chromosome 6q25.3, encoding Claudin-20 (P56880). Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.
This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions.
Source: NCBI Gene 49861 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 34 total
- MANE Select transcript:
NM_001001346
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:2042 |
| Approved symbol | CLDN20 |
| Name | claudin 20 |
| Location | 6q25.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000171217 |
| Ensembl biotype | protein_coding |
| Entrez | 49861 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000367165, ENST00000909656
RefSeq mRNA: 1 — MANE Select: NM_001001346
NM_001001346
CCDS: CCDS5249
Canonical transcript exons
ENST00000367165 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001433719 | 155264013 | 155264288 |
| ENSE00001443670 | 155275616 | 155276548 |
Expression profiles
Bgee: expression breadth ubiquitous, 158 present calls, max score 84.67.
Top tissues by expression
244 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| buccal mucosa cell | CL:0002336 | 84.67 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 76.34 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 68.82 | gold quality |
| bone marrow cell | CL:0002092 | 64.17 | silver quality |
| tendon | UBERON:0000043 | 63.84 | gold quality |
| adrenal tissue | UBERON:0018303 | 63.17 | gold quality |
| stromal cell of endometrium | CL:0002255 | 62.82 | gold quality |
| tibial nerve | UBERON:0001323 | 61.80 | gold quality |
| colonic epithelium | UBERON:0000397 | 61.46 | silver quality |
| calcaneal tendon | UBERON:0003701 | 61.04 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 60.48 | gold quality |
| right adrenal gland | UBERON:0001233 | 59.68 | gold quality |
| left adrenal gland | UBERON:0001234 | 58.44 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 58.43 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 58.06 | gold quality |
| gingival epithelium | UBERON:0001949 | 57.77 | gold quality |
| skin of abdomen | UBERON:0001416 | 57.76 | gold quality |
| adrenal gland | UBERON:0002369 | 57.73 | gold quality |
| apex of heart | UBERON:0002098 | 57.72 | gold quality |
| adrenal cortex | UBERON:0001235 | 57.28 | gold quality |
| medial globus pallidus | UBERON:0002477 | 56.81 | gold quality |
| gingiva | UBERON:0001828 | 56.66 | gold quality |
| monocyte | CL:0000576 | 56.61 | gold quality |
| sural nerve | UBERON:0015488 | 55.69 | silver quality |
| right lobe of thyroid gland | UBERON:0001119 | 55.56 | gold quality |
| skin of leg | UBERON:0001511 | 55.39 | gold quality |
| corpus callosum | UBERON:0002336 | 55.33 | gold quality |
| tonsil | UBERON:0002372 | 55.01 | gold quality |
| leukocyte | CL:0000738 | 54.84 | gold quality |
| body of uterus | UBERON:0009853 | 54.84 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.95 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): TP53, TP63
miRNA regulators (miRDB)
44 targeting CLDN20, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-559 | 99.95 | 72.28 | 3609 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-548AB | 99.95 | 71.31 | 3488 |
| HSA-MIR-548A-5P | 99.94 | 71.27 | 3482 |
| HSA-MIR-548AD-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AE-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AK | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AM-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AP-5P | 99.94 | 71.14 | 3489 |
| HSA-MIR-548AQ-5P | 99.94 | 71.34 | 3426 |
| HSA-MIR-548AR-5P | 99.94 | 71.28 | 3515 |
| HSA-MIR-548AS-5P | 99.94 | 71.22 | 3482 |
| HSA-MIR-548AU-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AY-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548B-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548BB-5P | 99.94 | 71.27 | 3509 |
| HSA-MIR-548C-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548D-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548H-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548I | 99.94 | 71.25 | 3481 |
| HSA-MIR-548J-5P | 99.94 | 71.14 | 3489 |
| HSA-MIR-548O-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548W | 99.94 | 71.24 | 3488 |
| HSA-MIR-548Y | 99.94 | 71.28 | 3514 |
| HSA-MIR-12133 | 99.92 | 71.82 | 2006 |
| HSA-MIR-6844 | 99.82 | 70.69 | 2423 |
| HSA-MIR-6739-5P | 99.80 | 67.87 | 2806 |
| HSA-MIR-6733-5P | 99.74 | 67.94 | 2759 |
| HSA-MIR-586 | 99.65 | 70.40 | 2051 |
| HSA-MIR-9851-3P | 99.63 | 69.68 | 1110 |
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Cldn20 | ENSMUSG00000091530 |
| rattus_norvegicus | Cldn20 | ENSRNOG00000073115 |
Paralogs (22): CLDN11 (ENSG00000013297), CLDN18 (ENSG00000066405), CLDN15 (ENSG00000106404), CLDN16 (ENSG00000113946), CLDN10 (ENSG00000134873), CLDN17 (ENSG00000156282), CLDN8 (ENSG00000156284), CLDN14 (ENSG00000159261), CLDN1 (ENSG00000163347), CLDN19 (ENSG00000164007), CLDN3 (ENSG00000165215), CLDN2 (ENSG00000165376), CLDN22 (ENSG00000177300), CLDN7 (ENSG00000181885), CLDN5 (ENSG00000184113), CLDN6 (ENSG00000184697), CLDN24 (ENSG00000185758), CLDN4 (ENSG00000189143), CLDN9 (ENSG00000213937), CLDN25 (ENSG00000228607), CLDN34 (ENSG00000234469), CLDN23 (ENSG00000253958)
Protein
Protein identifiers
Claudin-20 — P56880 (reviewed: P56880)
All UniProt accessions (2): A0A140VKA2, P56880
UniProt curated annotations — full annotation on UniProt →
Function. Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.
Subcellular location. Cell junction. Tight junction. Cell membrane.
Similarity. Belongs to the claudin family.
RefSeq proteins (1): NP_001001346* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR004031 | PMP22/EMP/MP20/Claudin | Family |
| IPR006187 | Claudin | Family |
| IPR017974 | Claudin_CS | Conserved_site |
Pfam: PF00822
UniProt features (12 total): topological domain 5, transmembrane region 4, chain 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P56880-F1 | 81.61 | 0.52 |
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-420029 | Tight junction interactions |
MSigDB gene sets: 30 (showing top):
GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, KEGG_TIGHT_JUNCTION, GOBP_CELL_CELL_ADHESION, chr6q25, TGACATY_UNKNOWN, GOCC_CELL_CELL_JUNCTION, KEGG_CELL_ADHESION_MOLECULES_CAMS, GOCC_ANCHORING_JUNCTION, REACTOME_TIGHT_JUNCTION_INTERACTIONS, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, REACTOME_CELL_JUNCTION_ORGANIZATION, KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION, GOCC_TIGHT_JUNCTION, SOX10_TARGET_GENES, MIR6844
GO Biological Process (3): cell adhesion (GO:0007155), calcium-independent cell-cell adhesion (GO:0016338), bicellular tight junction assembly (GO:0070830)
GO Molecular Function (3): structural molecule activity (GO:0005198), identical protein binding (GO:0042802), protein binding (GO:0005515)
GO Cellular Component (7): Golgi apparatus (GO:0005794), cytosol (GO:0005829), plasma membrane (GO:0005886), bicellular tight junction (GO:0005923), tight junction (GO:0070160), membrane (GO:0016020), anchoring junction (GO:0070161)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Cell-cell junction organization | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoplasm | 2 |
| cellular anatomical structure | 2 |
| cellular process | 1 |
| cell-cell adhesion | 1 |
| apical junction assembly | 1 |
| tight junction assembly | 1 |
| molecular_function | 1 |
| protein binding | 1 |
| binding | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| membrane | 1 |
| cell periphery | 1 |
| apical junction complex | 1 |
| tight junction | 1 |
| cell-cell junction | 1 |
| cell junction | 1 |
Protein interactions and networks
STRING
326 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CLDN20 | SCAF8 | Q9UPN6 | 610 |
| CLDN20 | TIAM2 | Q8IVF5 | 604 |
| CLDN20 | CNKSR3 | Q6P9H4 | 559 |
| CLDN20 | A0A2Q2T6B6 | A0A2Q2T6B6 | 527 |
| CLDN20 | G9CGD6 | G9CGD6 | 527 |
| CLDN20 | CLDN12 | P56749 | 519 |
| CLDN20 | CLDN23 | Q96B33 | 484 |
| CLDN20 | FILIP1 | Q7Z7B0 | 455 |
| CLDN20 | ITGA2 | P17301 | 414 |
| CLDN20 | TJP3 | O95049 | 376 |
| CLDN20 | CLDN24 | A6NM45 | 374 |
| CLDN20 | CDC50A | Q9NV96 | 365 |
| CLDN20 | NOX3 | Q9HBY0 | 322 |
| CLDN20 | TJP2 | Q9UDY2 | 317 |
| CLDN20 | NHLRC2 | Q8NBF2 | 301 |
IntAct
141 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CNIH3 | CLDN20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ANKRD46 | CLDN20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| IGFBP5 | CLDN20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM239 | CLDN20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAL | CLDN20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PLP1 | CLDN20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDN20 | CNIH3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDN20 | TMEM239 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDN20 | ANKRD46 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDN20 | PLP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDN20 | PDZD2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | PDZK1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | LNX2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | HTRA3 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| APBA3 | CLDN20 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | MAST2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | NHERF4 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | PICK1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | MAGI1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | PTPN13 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | LIN7C | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| CLDN20 | MPP2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
BioGRID (11): HIF1AN (Affinity Capture-MS), CLDN20 (Two-hybrid), CLDN20 (Two-hybrid), CLDN20 (Two-hybrid), MAL (Two-hybrid), ANKRD46 (Two-hybrid), TMEM239 (Two-hybrid), HIF1AN (Affinity Capture-MS), ACTA1 (Affinity Capture-MS), FYN (Affinity Capture-MS), APP (Reconstituted Complex)
ESM2 similar proteins: A1A5C7, A5D7H1, A6H7A0, A6NJW4, A6QLN9, A8MUP2, A8MXK1, B0BMW8, B0BNL6, O35393, O62657, O75078, P52875, P55244, P56880, P57791, Q08334, Q0V881, Q15768, Q16557, Q2M1K6, Q3SZQ2, Q3UHH2, Q4V899, Q5E9H2, Q5FYB0, Q5M7U7, Q5R6I6, Q5RCI5, Q5SQ64, Q642A6, Q6PCB0, Q7TPB4, Q8BM89, Q8BZH0, Q8N431, Q8N5I2, Q8R2R5, Q8R2Z5, Q8VE98
Diamond homologs: A0A8C0N7E5, A6NM45, C3VMW3, C9JDP6, D3ZQJ0, O00501, O14493, O15551, O19005, O35054, O54942, O75508, O88551, O88552, O95471, O95484, O95500, O95832, P56745, P56746, P56747, P56748, P56750, P56856, P56857, P56880, P57739, P78369, Q0VCN0, Q2HJ22, Q2KIY2, Q3B7N4, Q3MHK4, Q4R3L1, Q5E9L0, Q5I0E5, Q5QT56, Q5R8E5, Q60771, Q63400
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 86 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Ras activation upon Ca2+ influx through NMDA receptor | 5 | 50.1× | 2e-06 |
| Unblocking of NMDA receptors, glutamate binding and activation | 5 | 47.7× | 2e-06 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 5 | 47.7× | 2e-06 |
| Assembly and cell surface presentation of NMDA receptors | 10 | 44.5× | 1e-12 |
| Dopamine Neurotransmitter Release Cycle | 5 | 43.5× | 3e-06 |
| Long-term potentiation | 5 | 41.7× | 3e-06 |
| Neurexins and neuroligins | 11 | 38.0× | 8e-13 |
| Protein-protein interactions at synapses | 7 | 32.6× | 1e-07 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| establishment or maintenance of epithelial cell apical/basal polarity | 11 | 78.9× | 3e-16 |
| protein localization to synapse | 6 | 56.7× | 1e-07 |
| receptor clustering | 7 | 53.9× | 1e-08 |
| regulation of postsynaptic membrane neurotransmitter receptor levels | 7 | 42.8× | 4e-08 |
| protein-containing complex assembly | 9 | 12.7× | 3e-06 |
| cell-cell adhesion | 9 | 11.3× | 6e-06 |
| chemical synaptic transmission | 8 | 7.6× | 5e-04 |
| actin cytoskeleton organization | 6 | 5.9× | 1e-02 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
34 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 30 |
| Likely benign | 0 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
314 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:155264284:CCCAG:C | donor_loss | 0.9800 |
| 6:155264285:CCAG:C | donor_loss | 0.9800 |
| 6:155264286:CAG:C | donor_loss | 0.9800 |
| 6:155264289:GTAAG:G | donor_loss | 0.9800 |
| 6:155268594:G:T | donor_gain | 0.9700 |
| 6:155270039:TGG:T | donor_gain | 0.9700 |
| 6:155264165:A:G | donor_gain | 0.9100 |
| 6:155275614:A:AG | acceptor_gain | 0.9100 |
| 6:155275615:G:GG | acceptor_gain | 0.9100 |
| 6:155270040:G:GA | donor_gain | 0.9000 |
| 6:155272797:CA:C | donor_gain | 0.9000 |
| 6:155275709:A:C | donor_gain | 0.9000 |
| 6:155272128:T:G | acceptor_gain | 0.8800 |
| 6:155275600:T:TA | acceptor_loss | 0.8700 |
| 6:155275610:CCTTA:C | acceptor_loss | 0.8700 |
| 6:155275611:CTTAG:C | acceptor_loss | 0.8700 |
| 6:155275612:TTAGG:T | acceptor_loss | 0.8700 |
| 6:155275613:TA:T | acceptor_loss | 0.8700 |
| 6:155275614:A:G | acceptor_loss | 0.8700 |
| 6:155275615:G:A | acceptor_loss | 0.8700 |
| 6:155264289:G:GG | donor_gain | 0.8500 |
| 6:155268606:A:AG | donor_gain | 0.8400 |
| 6:155265938:A:T | acceptor_gain | 0.8000 |
| 6:155265943:G:C | acceptor_gain | 0.8000 |
| 6:155264778:AATGT:A | donor_gain | 0.7900 |
| 6:155270041:GAAG:G | donor_gain | 0.7900 |
| 6:155275616:G:T | acceptor_loss | 0.7800 |
| 6:155270095:G:T | donor_gain | 0.7700 |
| 6:155272135:CTG:C | acceptor_gain | 0.7700 |
| 6:155275596:GTTTT:G | acceptor_loss | 0.7700 |
AlphaMissense
1424 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 6:155275809:G:C | W30C | 0.986 |
| 6:155275809:G:T | W30C | 0.986 |
| 6:155275872:G:C | W51C | 0.978 |
| 6:155275872:G:T | W51C | 0.978 |
| 6:155276089:T:C | C124R | 0.974 |
| 6:155275999:G:A | G94R | 0.973 |
| 6:155275999:G:C | G94R | 0.973 |
| 6:155275999:G:T | G94W | 0.973 |
| 6:155276000:G:A | G94E | 0.972 |
| 6:155275870:T:A | W51R | 0.971 |
| 6:155275870:T:C | W51R | 0.971 |
| 6:155275807:T:A | W30R | 0.970 |
| 6:155275807:T:C | W30R | 0.970 |
| 6:155275865:G:A | G49E | 0.970 |
| 6:155275909:T:A | C64S | 0.963 |
| 6:155275910:G:C | C64S | 0.963 |
| 6:155275879:T:A | C54S | 0.961 |
| 6:155275880:G:C | C54S | 0.961 |
| 6:155276252:G:A | G178D | 0.961 |
| 6:155275981:T:C | C88R | 0.960 |
| 6:155276158:T:C | F147L | 0.958 |
| 6:155276160:T:A | F147L | 0.958 |
| 6:155276160:T:G | F147L | 0.958 |
| 6:155275864:G:A | G49R | 0.957 |
| 6:155275864:G:C | G49R | 0.957 |
| 6:155276102:C:A | A128E | 0.957 |
| 6:155276113:A:C | S132R | 0.957 |
| 6:155276115:T:A | S132R | 0.957 |
| 6:155276115:T:G | S132R | 0.957 |
| 6:155276104:G:A | G129R | 0.956 |
dbSNP variants (sampled 300 via entrez): RS1000377841 (6:155276812 T>G), RS1000567928 (6:155265084 G>A), RS1000632714 (6:155263517 C>A), RS1000671858 (6:155271790 A>C,G), RS1000707015 (6:155272065 G>A), RS1000778025 (6:155265334 T>C), RS1001056052 (6:155271846 T>A), RS1001307611 (6:155268248 T>C), RS1001337139 (6:155268685 C>A), RS1001369439 (6:155268875 A>C), RS1001498534 (6:155268267 CA>C,CAA), RS1002327942 (6:155275448 T>C), RS1002431434 (6:155266508 T>C), RS1002895379 (6:155272107 G>A), RS1003012097 (6:155276948 A>G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
4 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005756_4 | Dimensional psychopathology (Negative) | 1.000000e-06 |
| GCST005758_3 | Dimensional psychopathology (Arousal) | 9.000000e-07 |
| GCST008155_40 | Waist-hip ratio | 3.000000e-06 |
| GCST008159_56 | Waist-to-hip ratio adjusted for BMI | 4.000000e-06 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0009096 | negative domain measurement |
| EFO:0009099 | arousal domain measurement |
| EFO:0004343 | waist-hip ratio |
| EFO:0007788 | BMI-adjusted waist-hip ratio |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
6 total (human), top 6 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| butyraldehyde | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| Lead | decreases expression | 1 |
| Valproic Acid | decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Lactic Acid | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.